384 related articles for article (PubMed ID: 21798892)
1. Comparison of the epidemiology of anti-neutrophil cytoplasmic antibody-associated vasculitis between Japan and the U.K.
Fujimoto S; Watts RA; Kobayashi S; Suzuki K; Jayne DR; Scott DG; Hashimoto H; Nunoi H
Rheumatology (Oxford); 2011 Oct; 50(10):1916-20. PubMed ID: 21798892
[TBL] [Abstract][Full Text] [Related]
2. Renal vasculitis in Japan and the UK--are there differences in epidemiology and clinical phenotype?
Watts RA; Scott DG; Jayne DR; Ito-Ihara T; Muso E; Fujimoto S; Harabuchi Y; Kobayashi S; Suzuki K; Hashimoto H
Nephrol Dial Transplant; 2008 Dec; 23(12):3928-31. PubMed ID: 18565978
[TBL] [Abstract][Full Text] [Related]
3. Incidence of ANCA-associated primary renal vasculitis in the Miyazaki Prefecture: the first population-based, retrospective, epidemiologic survey in Japan.
Fujimoto S; Uezono S; Hisanaga S; Fukudome K; Kobayashi S; Suzuki K; Hashimoto H; Nakao H; Nunoi H
Clin J Am Soc Nephrol; 2006 Sep; 1(5):1016-22. PubMed ID: 17699321
[TBL] [Abstract][Full Text] [Related]
4. The Epidemiology of Antineutrophil Cytoplasmic Autoantibody-Associated Vasculitis in Olmsted County, Minnesota: A Twenty-Year US Population-Based Study.
Berti A; Cornec D; Crowson CS; Specks U; Matteson EL
Arthritis Rheumatol; 2017 Dec; 69(12):2338-2350. PubMed ID: 28881446
[TBL] [Abstract][Full Text] [Related]
5. Seasonal Influence on Development of Antineutrophil Cytoplasmic Antibody-Associated Vasculitis: A Retrospective Cohort Study Conducted at Multiple Institutions in Japan (J-CANVAS).
Yoshida Y; Nakamoto N; Oka N; Kidoguchi G; Hosokawa Y; Araki K; Ishitoku M; Watanabe H; Sugimoto T; Mokuda S; Kida T; Yajima N; Omura S; Nakagomi D; Abe Y; Kadoya M; Takizawa N; Nomura A; Kukida Y; Kondo N; Yamano Y; Yanagida T; Endo K; Matsui K; Takeuchi T; Ichinose K; Kato M; Yanai R; Matsuo Y; Shimojima Y; Nishioka R; Okazaki R; Takata T; Ito T; Moriyama M; Takatani A; Miyawaki Y; Ito-Ihara T; Kawaguchi T; Kawahito Y; Hirata S
J Rheumatol; 2023 Sep; 50(9):1152-1158. PubMed ID: 37263656
[TBL] [Abstract][Full Text] [Related]
6. Increasing incidence and prevalence of ANCA-associated vasculitis in Northern Norway.
Nilsen AT; Karlsen C; Bakland G; Watts R; Luqmani R; Koldingsnes W
Rheumatology (Oxford); 2020 Sep; 59(9):2316-2324. PubMed ID: 31859355
[TBL] [Abstract][Full Text] [Related]
7. Brief Report: Circulating Cytokine Profiles and Antineutrophil Cytoplasmic Antibody Specificity in Patients With Antineutrophil Cytoplasmic Antibody-Associated Vasculitis.
Berti A; Warner R; Johnson K; Cornec D; Schroeder D; Kabat B; Langford CA; Hoffman GS; Fervenza FC; Kallenberg CGM; Seo P; Spiera R; St Clair EW; Brunetta P; Stone JH; Merkel PA; Specks U; Monach PA;
Arthritis Rheumatol; 2018 Jul; 70(7):1114-1121. PubMed ID: 29693324
[TBL] [Abstract][Full Text] [Related]
8. Childhood-Onset ANCA- Associated Vasculitis: single center experience from Central California.
Singh D; Sukumaran S
Pediatr Rheumatol Online J; 2023 Jul; 21(1):66. PubMed ID: 37400890
[TBL] [Abstract][Full Text] [Related]
9. Protective Role of HLA-DRB1*13:02 against Microscopic Polyangiitis and MPO-ANCA-Positive Vasculitides in a Japanese Population: A Case-Control Study.
Kawasaki A; Hasebe N; Hidaka M; Hirano F; Sada KE; Kobayashi S; Yamada H; Furukawa H; Yamagata K; Sumida T; Miyasaka N; Tohma S; Ozaki S; Matsuo S; Hashimoto H; Makino H; Arimura Y; Harigai M; Tsuchiya N
PLoS One; 2016; 11(5):e0154393. PubMed ID: 27166610
[TBL] [Abstract][Full Text] [Related]
10. Prevalence of anti-neutrophil cytoplasmic antibody-associated vasculitis in the south of France, using the capture-recapture method.
Rubenstein E; Henneton P; Rivière S; Casanova ML; Broner J; Arnaud E; Oziol E; Le Quintrec M; Moranne O; Jorgensen C; Combe B; Bourdin A; Fontaine C; Schiffmann A; Fraison JB; Hallé O; Fraisse T; Veysseyre F; Taieb G; Aerts C; Crampette L; Alovisetti C; Guis L; Mehlal S; Papinaud L; Le Quellec A; Guilpain P; Mahr A
Rheumatology (Oxford); 2024 May; 63(6):1552-1559. PubMed ID: 37819770
[TBL] [Abstract][Full Text] [Related]
11. Association of antineutrophil cytoplasmic antibody (ANCA) specificity with demographic and clinical characteristics of patients with ANCA‑associated vasculitides.
Wójcik K; Masiak A; Jeleniewicz R; Jakuszko K; Brzosko I; Storoniak H; Kur-Zalewska J; Wisłowska M; Madej M; Hawrot-Kawecka A; Głuszko P; Kucharz EJ;
Pol Arch Intern Med; 2022 Mar; 132(3):. PubMed ID: 34985235
[TBL] [Abstract][Full Text] [Related]
12. The utility of the ACR/EULAR 2017 provisional classification criteria for granulomatosis with polyangiitis in Korean patients with antineutrophil cytoplasmic antibody-associated vasculitis.
Yoo J; Kim HJ; Ahn SS; Jung SM; Song JJ; Park YB; Lee SW
Clin Exp Rheumatol; 2018; 36 Suppl 111(2):85-87. PubMed ID: 29185957
[TBL] [Abstract][Full Text] [Related]
13. Myeloperoxidase-Antineutrophil Cytoplasmic Antibody (ANCA)-Positive Granulomatosis With Polyangiitis (Wegener's) Is a Clinically Distinct Subset of ANCA-Associated Vasculitis: A Retrospective Analysis of 315 Patients From a German Vasculitis Referral Center.
Schirmer JH; Wright MN; Herrmann K; Laudien M; Nölle B; Reinhold-Keller E; Bremer JP; Moosig F; Holle JU
Arthritis Rheumatol; 2016 Dec; 68(12):2953-2963. PubMed ID: 27333332
[TBL] [Abstract][Full Text] [Related]
14. Clinical outcomes of treatment of anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis based on ANCA type.
Unizony S; Villarreal M; Miloslavsky EM; Lu N; Merkel PA; Spiera R; Seo P; Langford CA; Hoffman GS; Kallenberg CM; St Clair EW; Ikle D; Tchao NK; Ding L; Brunetta P; Choi HK; Monach PA; Fervenza F; Stone JH; Specks U;
Ann Rheum Dis; 2016 Jun; 75(6):1166-9. PubMed ID: 26621483
[TBL] [Abstract][Full Text] [Related]
15. Clinical impact of subgrouping ANCA-associated vasculitis according to antibody specificity beyond the clinicopathological classification.
Deshayes S; Martin Silva N; Khoy K; Yameogo S; Mariotte D; Lobbedez T; Aouba A
Rheumatology (Oxford); 2019 Oct; 58(10):1731-1739. PubMed ID: 30805643
[TBL] [Abstract][Full Text] [Related]
16. The complexity of classifying ANCA-associated small-vessel vasculitis in actual clinical practice: data from a multicenter retrospective survey.
Corral-Gudino L; González-Vázquez E; Calero-Paniagua I; Pérez-Garrido L; Cusacovich I; Rivas-Lamazares A; Quesada-Moreno A; González-Fernández A; Mora-Peña D; Lerma-Márquez JL; Del-Pino-Montes J
Rheumatol Int; 2020 Feb; 40(2):303-311. PubMed ID: 31385079
[TBL] [Abstract][Full Text] [Related]
17. Life-threatening onset of systemic vasculitis requiring intensive care unit admission: a case series.
Monti S; Montecucco C; Pieropan S; Mojoli F; Braschi A; Caporali R
Clin Exp Rheumatol; 2015; 33(2 Suppl 89):S-126-31. PubMed ID: 26016763
[TBL] [Abstract][Full Text] [Related]
18. Methotrexate versus cyclophosphamide for remission maintenance in ANCA-associated vasculitis: A randomised trial.
Maritati F; Alberici F; Oliva E; Urban ML; Palmisano A; Santarsia F; Andrulli S; Pavone L; Pesci A; Grasselli C; Santi R; Tumiati B; Manenti L; Buzio C; Vaglio A
PLoS One; 2017; 12(10):e0185880. PubMed ID: 29016646
[TBL] [Abstract][Full Text] [Related]
19. Hypothyroidism in vasculitis.
Kermani TA; Cuthbertson D; Carette S; Khalidi NA; Koening CL; Langford CA; McAlear CA; Monach PA; Moreland L; Pagnoux C; Seo P; Specks U; Sreih A; Warrington KJ; Merkel PA;
Rheumatology (Oxford); 2022 Jul; 61(7):2942-2950. PubMed ID: 34730828
[TBL] [Abstract][Full Text] [Related]
20. Tobacco differentially affects the clinical-biological phenotypes of ANCA-associated vasculitides.
Benarous L; Terrier B; Puéchal X; Dunogué B; Cohen P; Le Jeunne C; Mouthon L; Guillevin L;
Clin Exp Rheumatol; 2015; 33(2 Suppl 89):S-116-21. PubMed ID: 26016761
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
